UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atr
Go back to UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atr| (NASDAQ: ELAB) | Delayed: 1.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.32 | 52 Week High | $ | |||
| Open | $1.32 | 52 Week Low | $ | |||
| Day High | $1.32 | P/E | N/A | |||
| Day Low | $1.32 | EPS | $ | |||
| Volume | 23,910 | |||||
